Asimov is a tools company developing a synthetic biology platform – from cells to software – to enable better design & manufacture of next-generation therapeutics. Asimov’s CHO Edge System for biologic production routinely achieves titers of 8–11 g/L across modalities, and minimizes the risk of cell line development by enabling exploration of vector design space. Asimov is applying the same approach to improve cell & gene therapies, by developing best-in-class stable & semi-stable lentiviral cell lines as well as stable AAV producer cell lines, and enhancing safety profiles through the creation of synthetic tissue-specific promoters.

SOLUTIONS

  • Asimov - CHO Edge
    CHO Edge System

    Achieve high monoclonal antibody and complex bispecific titers routinely with an IND-approved cell line development platform that integrates genetic tools and data-driven models.

  • Asimov - LVEdge
    LV Edge System

    By transitioning from a 4-plasmid transient system to 1- or 0-plasmid configurations, the LV Edge systems reduce or eliminate the need for GMP plasmids, lowering costs and supply chain risks.

  • Asimov - AAV Edge
    AAV Edge System

    Learn about a modular tool suite capable of achieving titers up to 6E15 vg/L. Move from transfection to stable cell lines in just 20 weeks using AI-driven optimization and robust host platforms.

VIDEOS

33:17 Asimov - Raja talk
Model-Driven Genetic Design And Bioprocess Optimization Across Modalities

Traditional biomanufacturing relies too heavily on trial and error. By integrating AI and mechanistic models into early design, developers can overcome productivity limits and accelerate timelines for complex therapeutic modalities.

CONTACT INFORMATION

Asimov

201 Brookline Ave, Suite 1201

Boston, MA 02215

UNITED STATES

ASIMOV NEWS